News & Updates
Showing Oncology articles
Showing
Induction chemo followed by chemoradiotherapy bumps up survival in advanced cervical cancer
A short-course induction chemotherapy conducted prior to chemoradiotherapy appears to deliver significant survival boost in locally advanced cervical cancer, according to the phase III GCIG INTERLACE trial.
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment
The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.
1L nab-paclitaxel + S-1 extends PFS and OS vs nab-paclitaxel + gemcitabine in Chinese patients with advanced pancreatic cancer
A phase II trial demonstrated significantly longer progression-free survival (PFS) and overall survival (OS) in Chinese patients with advanced pancreatic cancer (APC) who received first-line treatment with nab-paclitaxel plus S-1 (AS) vs nab-paclitaxel plus gemcitabine (AG).
Prior local therapy enhances apalutamide’s effect on metastasis-free survival
A secondary post hoc analysis of the phase III SPARTAN trial shows that patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who received prior prostate-directed local therapy (LT) had longer metastasis-free survival (MFS) when treated with apalutamide vs those without prior LT.
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.